Melissa McBurnie

Alloy Ventures, Inc. is an independent Venture Capital firm founded in 1984 by Craig C. Taylor, John F. Shoch and Tony Di Bona. The firm is headquartered in Palo Alto, California.

Pharma Ventures Ltd. provides advisory services on life sciences transactions. It offers mergers and acquisitions, licensing, strategy and valuation, and expert services. The firm's industry coverage includes pharmaceuticals, biologics, drug delivery systems, diagnostics, medical devices, including telemedicine, medical software. The company is headquartered in Oxford, the United Kingdom.

The University of Melbourne, founded in 1853, is a world-renowned institution located in Parkville, Australia. The university is a leader in education, teaching, and research, offering a wide range of coursework and research programs.

Helmsman Funds Management Pty Ltd (Helmsman Capital) is a private equity firm founded in 2002 by Douglas Potter and Ian Johnson. The firm is headquartered in Sydney, Australia.

Hatchtech Pty Ltd. operates as pharmaceutical product company. It offers Xeglyze lotion that is head lice treatment. The company was founded by Vernon Morrison Bowles in 2001 and is headquartered in in Melbourne, Australia.

Medical Research Commercialisation Fund Trust invests in life science companies located in Australia. The fund focuses on companies operating in the fields of medical research institutes and allied research hospitals. It provides seed and early stage financing in project investment of up to $0.02 million, at the stage of company formation invests up to $4 million and also makes follow-on investments of up to $2 million. It seeks co-investment with other investors for technologies with larger capital requirements.

AusBiotech Ltd. operates as an Australian biotechnology membership company. The private company is based in Melbourne, Australia. and has subsidiaries in Australia. The company was founded by Liz Dallimore. Lorraine Chiroiu has been the CEO of the company since 2008.

Fibrotech Therapeutics Pty Ltd develops novel drug candidates for the treatment of the fibrosis prevalent in such chronic conditions as kidney disease, chronic heart failure, pulmonary fibrosis, and arthritis. The company was founded by Richard Ernest Gilbert, Darren James Kelly, Spencer J Williams, Steven C Zammit, David Stapleton, Henry Krum and Yuan Zhang in 2006 and is headquartered in Melbourne, Australia.

Elastagen Pty Ltd. produces and develops synthetic human elastin for medical device applications. Its products include skin rejuvenation, scar remodeling, skin tissue repair, wound healing, surgical glues and sealants. The firm developed a Elastatherapy treatments which offer the chance to restore the levels of Elastin in human skin, with benefits anticipated in both medical dermatology and cosmetic applications. The company was founded by Anthony Weiss in 2003 and is headquartered in Sydney, Australia.

Otifex Therapeutics Pty Ltd. develops treatment for ear diseases. The company was founded by Burkhard Franz and Colin Anderson in 2009 and is headquartered in Melbourne, Australia.

PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia.

Global Kinetics Pty Ltd. provides point of care measurement and reporting of Parkinson's disease motor symptoms. Its product includes Personal KinetiGraph (PKG), a wrist worn medical device which reminds the patient when they have taken Levodopa medication as prescribed by doctor. The company was founded by Robert Griffiths and Malcolm Horne in 2007 and is headquartered in Melbourne, Australia.

Q-Sera Pty Ltd. develops, manufactures and markets blood serum collection tubes. The company was founded in 2012 and is headquartered in Melbourne, Australia.

QUE Oncology, Inc. engages in preventing and treating life-threatening cancers such as prostate cancer, breast cancer, melanoma, and cancer pain; and related conditions. The company is headquartered in Atlanta, GA.

OccuRx Pty Ltd provides biopharmaceutical services. It engages in the development of therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis and inflammation. The company was founded by Darren J. Kelly in 2014 and is headquartered in Melbourne, Australia.

MecRx Pty Ltd. develops drugs for treatment of cancer. The company was founded by Ian Holmes, Jo Alcindor, Tom Peat and Janet Newman in 2013 and is headquartered in Melbourne, Australia.

Azura Ophthalmics Ltd. develops therapies for meibomian gland dysfunction. It offers a portfolio of compounds in combination with a novel drug delivery platform to advance a portfolio of treatments for meibomian gland dysfunction. The company was founded by Yair Alster in 1980 and is headquartered in Tel Aviv, Israel.

Protego Medical Pty Ltd. operates as an early stage medical technology company developing a medical device for sternal protection during cardiac surgery. The firm offers Sternal Haemostasis and protection during cardiac surgery, and Sternal Protection Device (SPD). The company was founded in 2013 and is headquartered in Melbourne, Australia.

OncoRes Medical Pty Ltd. develops an imaging medical device which provides micro-scale images of tissue stiffness and elasticity information to surgeons. The company is headquartered in Nedlands, Australia.

Cardiora Pty Ltd. functions as a clinical stage pharmaceutical company. It develops CRD-102, an oral medicine for heart failure. The company was founded by David Kaye in 2015 and is headquartered in Melbourne, Australia.

Baker Heart & Diabetes Institute owns and operates a medical research institute. The company is headquartered in Melbourne, Australia.

Cincera Therapeutics Pty Ltd. is a biotechnology company, which develops molecule drugs. It focuses on the discovery and development of new small molecule drugs aiming to treat difficult-to-treat inflammatory and fibrotic conditions associated with obesity and metabolic disorders, with potential applications in many other disease areas including cancer. The company was founded by Bernard Flynn and Stuart Pitson and is headquartered in Melbourne, Australia.

Certa Therapeutics Pty Ltd. operates as biotechnology company. The firm develops drugs for treatment for kidney disease. The company was founded by Darren James Kelly and is headquartered in Melbourne, Australia.

Denteric Pty Ltd. is a biotechnology company focused on oral health. It provides developing vaccines for treating and preventing severe periodontal disease. The company was founded by Eric C. Reynolds and is headquartered in Melbourne, Australia.

Pathios Therapeutics Ltd. engages in discovering and developing novel small molecule drugs. The company was founded by Thomas David McCarthy, Alan Naylor, Kirsty McCarthy, Peter Joyce and Someit Sidhu in 2017 and is headquartered in Oxford, the United Kingdom.

Myricx Pharma Ltd. engages in the development of novel proprietary inhibitors of human N-myristoyltransferases. The company was founded by Ed Tate, Roberto Solari, and Andrew Bell in 2019 and is headquartered in Stevenage, the United Kingdom.

Respirion Pharmaceuticals Pty Ltd. operates as a biotechnology firm. It focuses on development new treatments for respiratory diseases. The company was founded by Barry Clements in 2018 and is headquartered in Iluka, Australia.

Australian Investment Council is an Australian private company located in Sydney. The firm operates as an association. Navleen Prasad has been the CEO since 2022.

George Medicines UK Ltd. is a company focused on late stage drug development to improve the management of non-communicable diseases. The company is based in London, UK. The British company does this by creating single-pill, multi-mechanism combinations of existing medicines. Stefan König has been the CEO of the company since 2021.

ReGen Ventures Management Pty Ltd (ReGen Ventures) is a venture capital firm founded in 2020 by Fitzgerald Daniel. The firm is headquartered in Byron Bay, Australia.